US 10-year Treasury yields surpassed 5%, reaching levels not seen since 2007, prompting bond investors to reconsider medium-term bonds (5-10 years) as attractive income options. Despite ongoing rate hikes and economic uncertainties, higher yields provide a "price cushion," reducing potential losses even if rates rise further. Experts suggest that bonds with durations under five years offer better protection, while those in the 5-10 year range offer the best balance of yield and risk. This environment may encourage investors to shift some assets from stocks to bonds for stable income, especially if yields remain elevated over the next several months.
The beaten-up bond market and its yield dynamics provide context for Pluang's market snapshot. For readers following US stocks, here is Pluang's market snapshot as of Sep 15, 2026 23:03 WIB: out of 150 priced US stocks tradable on Pluang, 35 rose and 114 fell today. Notable movers include CVNA (Carvana Co) at USD 67.94 with a -4.13% change, QCOM (QUALCOMM, Inc.) at USD 187.49 with a +4.07% change, and PINS (Pinterest Inc) at USD 18.93 with a -3.83% change.
Uber Technologies reported a 25% year-over-year increase in gross bookings to $53.7 billion in Q1 2026, driven by growth in ride-hailing, delivery, grocery, retail, and membership services. CEO Dara Khosrowshahi's recent purchase of 141,000 shares wo...
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...
